Prospective Evaluation of the Fluid Rapid Influenza Test

PHASE3SuspendedINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2009

Conditions
Influenza
Interventions
DEVICE

fluID Rapid Influenza Test

The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).

Trial Locations (13)

11215

New York Methodist Hospital, Brooklyn

27103

Forsyth Medical Center, Winston-Salem

32720

University Clinical Research - DeLand, LLC, DeLand

48235

Sinai Grace Hospital, Detroit

53226

Medical College of Wisconsin, Milwaukee

55415

Hennepin County Medical Center, Minneapolis

63110

Washington University at St. Louis, St Louis

64108

Children's Mercy Hospital, Kansas City

71103

Louisiana State University Health Sciences Center, Shreveport

71115

The Family Doctor Research, Shreveport

84015

Granger Medical Clinic, West Valley City

92152

Naval Health Research Center, San Diego

Unknown

University of Hong Kong, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Nanogen, Inc.

INDUSTRY

NCT00826709 - Prospective Evaluation of the Fluid Rapid Influenza Test | Biotech Hunter | Biotech Hunter